

# A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573

---

**Status** RECRUITING  
**Sponsor** Amryt Pharma  
**Enrollment** 580 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Patients with a confirmed diagnosis of dystrophic EB or junctional EB

### Exclusion (1)

- None

## Locations (5 total)

---

CHU de Toulouse, Hôpital Larrey, Toulouse, France  
Hospital of Skin and Venereal Diseases of Thessaloniki, Thessaloniki, Greece  
Hospital Clinic, Barcelona, Barcelona, Spain  
... and 2 more locations